KARFİLZOMİB-DEKSAMETAZON(KD)(Car-Dex) PROTOKOLÜ

Kaynaklar:

1-Facon, T, Niesvizky, R, Mateos, MV, et al. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Adv 2020; 4: 5449–5459.

2-Dimopoulos, MA, Quach, H, Mateos, M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: updated efficacy and safety results of the phase 3 candor study. Blood 2020; 136: 26–27.

3-Berenson, JR, Cartmell, A, Bessudo, A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood 2016; 127: 3360–3368.